Novel Pathways and Endogenous Mediators in Anti-Inflammation and Resolution

Chemical Immunology and Allergy

Volumn 83, Issue , 2003, Pages 115-145

  Serhan, Charles N ^a,b   Levy, Bruce ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONATE 15 LIPOXYGENASE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 4; LEUKOTRIENE A4; LIPOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTANOID; TUMOR NECROSIS FACTOR; ARACHIDONATE 5 LIPOXYGENASE; HYDROXYICOSATETRAENOIC ACID; LIPOXIN A; PROSTAGLANDIN;

ANIMAL MODEL; ASTHMA; CELL INTERACTION; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; GLOMERULONEPHRITIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; LEUKOCYTE; LIQUID CHROMATOGRAPHY; LUNG DISEASE; MASS SPECTROMETRY; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; THROMBOCYTE; ANIMAL; BIOSYNTHESIS; CELL COMMUNICATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; ASPIRIN; CELL COMMUNICATION; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; INFLAMMATION; LEUKOTRIENE A4; LIPOXINS; PROSTAGLANDINS;

EID: 0141799938     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000071558     Document Type: Review

References (134)

1. Majno G, Joris I: Cells, Tissues and Disease: Principles of General Pathology. Cambridge, Blackwell Science, 1996, p 974.
2. Gallin JI, Snyderman R, Fearon DT, Haynes BF, Nathan C: Inflammation: Basic Principles and Clinical Correlates. Philadelphia, Lippincott Williams & Wilkins, 1999, p 1360.
3. Samuelsson B, Dahlén SE, Lindgren JA, Rouzer CA, Serhan CN: Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 1987;237:1171-1176.
4. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K: Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000;192:1197-1204.
5. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac R-L: Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med 2002;196:1025-1037.
6. Serhan CN, Ward PA: Molecular and Cellular Basis of Inflammation. Totawa, Humana Press, 1999.
7. Serhan CN, Haeggström JZ, Leslie CC: Lipid mediator networks in cell signaling: Update and impact of cytokines. FASEB J 1996;10:1147-1158.
8. 4 biosynthesis by endogenous adenosine in ligand-activated human neutrophils. J Exp Med 1997;186:1401-1406.
9. Qiu F-H, Wada K, Stahl GL, Serhan CN: IMP and AMP deaminase in reperfusion injury down-regulates neutrophil recruitment. Proc Natl Acad Sci USA 2000;97:4267-4272.
10. Serhan CN: Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim Biophys Acta 1994;1212:1-25.
11. 4. J Pharmacol Exp Ther 2002;300:385-392.
12. de Waal Malefyt R: Role of interleukin-10, interleukin-4, and interleukin-13 in resolving inflammatory responses; in Gallin JI, Snyderman R, Fearon DT, Haynes BF, Nathan C (eds): Inflammation: Basic Principles and Clinical Correlates. Philadephia, Lippincott Williams & Wilkins, 1999, pp 837-849.
13. Diamond P, McGinty A, Sugrue D, Brady HR, Godson C: Regulation of leukocyte trafficking by lipoxins. Clin Chem Lab Med 1999;37:293-297.
14. 4 are potent stimuli for human monocyte migration and adhesion: Selective inactivation by dehydrogenation and reduction. J Exp Med 1996;183:137-146.
15. Marcus AJ: Aspirin as prophylaxis against colorectal cancer. N Engl J Med 1995;333:656-658.
16. Vane JR: Adventures and excursions in bioassay: The stepping stones to prostacyclin; in Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures. Stockholm, Almqvist & Wiksell, 1982, pp 181-206.
17. 4 ELISA. J Pharmacol Exp Ther 1998;287:779-790.
18. Clària J, Serhan CN: Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 1995;92:9475-9479.
19. Clària J, Lee MH, Serhan CN: Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med 1996;2:583-596.
20. Showell HJ, Cooper K: Inhibitors and antagonists of cyclooxygenase, 5-lipoxygenase, and platelet activating factor; in Gallin JI, Snyderman R (eds): Inflammation: Basic Principles and Clinical Correlates. Philadelphia, Lippincott Williams & Wilkins, 1999, pp 1177-1193.
21. Malaviya R, Abraham SN: Role of mast cell leukotrienes in neutrophil recruitment and bacterial clearance in infectious peritonitis. J Leukoc Biol 2000;67:841-846.
22. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel D, Quan H, Larson PJ, Schwartz JI, Musliner T, Gertz BJ, Brater DC, Yao SL: Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: A randomized, controlled trial. Ann Intern Med 2000;133:1-9.
23. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, Ehrich E, Mukhopadhyay S, Daniels B: Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000;43:978-987.
24. 4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995;34:14609-14615.
25. Serhan CN: Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): A jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins 1997;53:107-137.
26. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN: Lipid mediator class switching during acute inflammation: Signals in resolution. Nat Immunol 2001;2:612-619.
27. 4 up-regulate transcriptional corepressor NAB1 in human neutrophils. FASEB J 2001;15:2736-2738 (available at www.fasebj.org).
28. Varani J, Ward PA: Mechanism of neutrophil-dependent and neutrophil-independent endothelial cell injury. Biol Signals 1994;3:1-14.
29. 4 by platelet 12-lipoxygenase in vitro. J Clin Invest 1990;85:772-780.
30. Edenius C, Stenke L, Lindgren JA: On the mechanism of transcellular lipoxin formation in human platelets and granulocytes. Eur J Biochem 1991;199:401-409.
31. Lehr H-A, Frei B, Arfors K-E: Vitamin C prevents cigarette smoke-induced leukocyte aggregation and adhesion to endothelium in vivo. Proc Natl Acad Sci USA 1994;91:7688-7692.
32. Brady HR, Serhan CN: Adhesion promotes transcellular leukotriene biosynthesis during neutrophil-glomerular endothelial cell interactions: Inhibition by antibodies against CD18 and L-selectin. Biochem Biophys Res Commun 1992;186:1307-1314.
33. Herschman HR: Recent progress in the cellular and molecular biology of prostaglandin synthesis. Trends Cardiovasc Med 1998;8:145-150.
34. Samuelsson B: From studies of biochemical mechanisms to novel biological mediators: Prostaglandin endoperoxides, thromboxanes and leukotrienes; in Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures. Stockholm, Almqvist & Wiksell, 1982, pp 153-174.
35. 4 receptors. J Exp Med 2000;192:F5-F8.
36. 4 and epoxytetraenes: Stabilization of eicosanoids by liposomes. Biochem Biophys Res Commun 1989;159:477-481.
37. Nassar GM, Morrow JD, Roberts LJ 2nd, Lakkis FG, Badr KF: Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J Biol Chem 1994;269:27631-27634.
38. Levy BD, Romano M, Chapman HA, Reilly JJ, Drazen J, Serhan CN: Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J Clin Invest 1993;92:1572-1579.
39. Libby P: Atherosclerosis: The new view. Sci Am 2002;286:46-55.
40. Levy GN: Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J 1997;11:234-247.
41. 2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Circulation 1995;92:3194-3200.
42. Sneader W: The discovery of aspirin: A reappraisal. BMJ 2000;321:1591-1594.
43. 4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Clin Sci 1989;77:195-203.
44. 4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol 1996;156:2264-2272.
45. 4 inhibit tumor necrosis factor 1α-initiated neutrophil responses and trafficking: Regulators of a cytokine-chemokine axis. J Exp Med 1999;189:1923-1929.
46. 4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin Invest 1993;92:75-82.
47. Canny G, Levy O, Furuta GT, Narravula-Alipati S, Sisson RB, Serhan CN, Colgan SP: Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci USA 2002;99:3902-3907.
48. 4 stable analogs are potent inhibitors of acute inflammation: Evidence for antiinflammatory receptors. J Exp Med 1997;185:1693-1704.
49. 4 stable analogues. J Clin Invest 1998;101:819-826.
50. Clish CB, O'Brien JA, Gronert K, Stahl GL, Petasis NA, Serhan CN: Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci USA 1999;96:8247-8252.
51. 4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: Relationship with concurrent eosinophilia. J Immunol 2000;164:1029-1036.
52. 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest 1999;104:309-316.
53. 4 analogs. J Clin Invest 1998;101:1860-1869.
54. 4 and regulation of vascular and inflammatory responses. Am J Pathol 2001;158:3-9.
55. 4 inhibits cholinergic neurotransmission through nitric oxide generation in the rabbit trachea. Eur J Pharmacol 1995;287:233-238.
56. Serhan CN, Hamberg M, Samuelsson B: Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 1984;81:5335-5339.
57. Ford-Hutchinson AW: Arachidonate 15-lipoxygenase; characteristics and potential biological significance. Eicosanoids 1991;4:65-74.
58. Sigal E, Conrad DJ: Human 15-lipoxygenase: A potential effector molecule for interleukin-4. Adv Prostaglandin Thromboxane Leukot Res 1994;22:309-316.
59. Katoh T, Lakkis FG, Makita N, Badr KF: Co-regulated expression of glomerular 12/15-lipoxygenase and interleukin-4 mRNA in rat nephrotoxic nephritis. Kidney Int 1994;46:341-349.
60. 2-like' cells in allergy and asthma: Pharmacological perspectives. Trends Pharmacol Sci 1994;15:324.
61. Pouliot M, McDonald PP, Borgeat P, McColl SR: Granulocyte/macrophage colony-stimulating factor stimulates the expression of the 5-lipoxygenase-activating protein (FLAP) in human neutrophils. J Exp Med 1994;179:1225-1232.
62. Ring WL, Riddick CA, Baker JR, Munafo DA, Bigby TD: Lymphocytes stimulate expression of 5-lipoxygenase and its activating protein in monocytes in vitro via granulocyte-macrophage colony stimulating factor and interleukin-3. J Clin Invest 1996;97:1293-1301.
63. L'Heureux GP, Bourgoin S, Jean N, McColl SR, Naccache PH: Diverging signal transduction pathways activated by interleukin-8 and related chemokines in human neutrophils: Interleukin-8, but not NAP-2 or GROAα, stimulates phospholipase D activity. Blood 1995;85:522-531.
64. 4: Comparison of icosanoids having bronchoconstrictor and vasodilator actions but lacking platelet aggregatory activity. Proc Natl Acad Sci USA 1988;85:8340-8344.
65. Dahlén S-E, Serhan CN: Lipoxins: Bioactive lipoxygenase interaction products; in Wong A, Crooke ST (eds): Lipoxygenases and Their Products. San Diego, Academic Press, 1991, pp 235-276.
66. 4: Structure-function relationships. Biochem Biophys Res Commun 1991;180:1416-1421.
67. 4 in rat glomerular mesangial cells: Evidence for competition at a common receptor. Proc Natl Acad Sci USA 1989;86:3438-3442.
68. Fiore S, Serhan CN: Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J Exp Med 1990;172:1451-1457.
69. Chavis C, Chanez P, Vachier I, Bousquet J, Michel FB, Godard P: 5,15-diHETE and lipoxins generated by neutrophils from endogenous arachidonic acid as asthma biomarkers. Biochem Biophys Res Commun 1995;207:273-279.
70. Chavis C, Vachier I, Chanez P, Bousquet J, Godard P: 5(S),15(S)-Dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: Dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. J Exp Med 1996;183:1633-1643.
71. Thomas E, Leroux JL, Blotman F, Chavis C: Conversion of endogenous arachidonic acid to 5,15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis. Inflamm Res 1995;44:121-124.
72. Shen J, Herderick E, Cornhill JF, Zsigmond E, Kim H-S, Kühn H, Guevara NV, Chan L: Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 1996;98:2201-2208.
73. Brezinski ME, Serhan CN: Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: Agonist-induced deacylation and transformation of stored hydroxyeicosanoids. Proc Natl Acad Sci USA 1990;87:6248-6252.
74. 4 receptor that is conserved in structure and function. Br J Pharmacol; in press.
75. Edenius C, Haeggström J, Lindgren JA: Transcellular conversion of endogenous arachidonic acid to lipoxins in mixed human platelet-granulocyte suspensions. Biochem Biophys Res Commun 1988;157:801-807.
76. 4 transfer. Trends Pharmacol Sci 1993;14:351-354.
77. Corey EJ, Mehrotra MM: A stereoselective and practical synthesis of 5,6(S,S)-epoxy-15(S)-hydroxy-7(E),9(E),11(Z),13(E)-eicosatetraenoic acid (4), possible precursor of the lipoxins. Tetrahedron Lett 1986;27:5173-5176.
78. Sheppard KA, Greenberg SM, Funk CD, Romano M, Serhan CN: Lipoxin generation by human megakaryocyte-induced 12-lipoxygenase. Biochim Biophys Acta 1992;1133:223-234.
79. Romano M, Serhan CN: Lipoxin generation by permeabilized human platelets. Biochemistry 1992;31:8269-8277.
80. Romano M, Chen XS, Takahashi Y, Yamamoto S, Funk CD, Serhan CN: Lipoxin synthase activity of human platelet 12-lipoxygenase. Biochem J 1993;296:127-133.
81. Lehr H-A, Olofsson AM, Carew TE, Vajkoczy P, von Andrian UH, Hübner C, Berndt MC, Steinberg D, Messmer K, Arfors KE: P-selectin mediates the interaction of circulating leukocytes with platelets and microvascular endothelium in response to oxidized lipoprotein in vivo. Lab Invest 1994;71:380-386.
82. Mayadas TN, Mendrick DL, Brady HR, Tang T, Papayianni A, Assmann KJM, Wagner DD, Hynes RO, Cotran RS: Acute passive anti-glomerular basement membrane nephritis in P-selectin-deficient mice. Kidney Int 1996;49:1342-1349.
83. 4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int 1995;47:1295-1302.
84. Fiore S, Brezinski ME, Sheppard KA, Serhan CN: The lipoxin biosynthetic circuit and their actions with human neutrophils. Adv Exp Med Biol 1991;314:109-132.
85. Edenius C, Kumlin M, Björk T, Anggard A, Lindgren JA: Lipoxin formation in human nasal polyps and bronchial tissue. FEBS Lett 1990;272:25-28.
86. Tornhamre S, Gigou A, Edenius C, Lellouche JP, Lindgren JA: Conversion of 5,6-dihydroxyeicosatetraenoic acids. A novel pathway for lipoxin formation by human platelets. FEBS Lett 1992;304:78-82.
87. Rowley AF, Hill DJ, Ray CE, Munro R: Haemostasis in fish - An evolutionary perspective. Thromb Haemost 1997;77:227-233.
88. Gronert K, Virk SM, Herman CA: Thrombocytes are the predominant source of endogenous sulfidopeptide leukotrienes in the bullfrog (Rana catesbeiana). Biochim Biophys Acta 1995;1255:311-319.
89. 4 receptor. J Biol Chem 1997;272:6972-6978.
90. Stenke L, Reizenstein P, Lindgren JA: Leukotrienes and lipoxins - New potential performers in the regulation of human myelopoiesis. Leuk Res 1994;18:727-732.
91. Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta 1996;1299:125-140.
92. Xiao G, Tsai A-L, Palmer G, Boyar WC, Marshall PJ, Kulmacz RJ: Analysis of hydroperoxide-induced tyrosyl radicals and lipoxygenase activity in aspirin-treated human prostaglandin H synthase-2. Biochemistry 1997;36:1836-1845.
93. Hennekens C, Jonas M, Buring J: The benefits of aspirin in acute myocardial infarction. Still a well-kept secret in the United States. Arch Intern Med 1994;154:37-39.
94. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE: Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-614.
95. 4. FASEB J 2002;16:1937-1939.
96. Sanak M, Levy BD, Clish CB, Chiang N, Gronert K, Mastalerz L, Serhan CN, Szczeklik A: Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000;16:44-49.
97. Clària J, Titos E, Jiménez W, Ros J, Ginès P, Arroyo V, Rivera F, Rodés J: Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. Gastroenterology 1998;115:147-156.
98. 4 and decreased lipoxin formation in chronic myeloid leukemia. Adv Prostaglandin Thromboxane Leukot Res 1990;21B:883-886.
99. Stenke L, Edenius C, Samuelsson J, Lindgren JA: Deficient lipoxin synthesis: A novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood 1991;78:2989-2995.
100. Stenke L, Nasman-Glaser B, Edenius C, Samuelsson J, Palmblad J, Lindgren JA: Lipoxygenase products in myeloproliferative disorders: Increased leukotriene C4 and decreased lipoxin formation in chronic myeloid leukemia. Adv Prostaglandin Thromboxane Leukot Res 1991;21B:883-886.
101. Stenke L, Mansour M, Edenius C, Reizenstein P, Lindgren JA: Formation and proliferative effects of lipoxins in human bone marrow. Biochem Biophys Res Commun 1991;180:255-261.
102. 4 analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: A role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 2000;39:4761-4768.
103. 4. Impact of aspirin therapy. Circulation 1992;86:56-63.
104. 4 analogs with increased biologic activity. FASEB J 1998;12:487-494.
105. 4 metabolic inactivation. J Biol Chem 2000;275:25372-25380.
106. 4 receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med 2000;191:1197-1207.
107. 4, and their analogs selectively downregulate PMN azurophilic degranulation. Am J Physiol 1999;276:C988-C994.
108. 4 stable analogs are demonstrable in human whole blood: Modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions. Blood 1999;94:4132-4142.
109. 4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am Rev Respir Dis 1990;141:1453-1458.
110. 4-ELISA. Lipids 1993;28:1047-1053.
111. Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, Schmidt BA, Szczeklik W, Drazen JM, Serhan CN: Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med 2002;8:1018-1023.
112. De Bie JJ, Hessel EM, Van Ark I, Van Esch B, Hofman G, Nijkamp FP, Van Oosterhout AJ: Effect of dexamethasone and endogenous corticosterone on airway hyperresponsiveness and eosinophilia in the mouse. Br J Pharmacol 1996;119:1484-1490.
113. Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J, Ford-Hutchinson AW, Gauthier JY, Lord A, Masson P: Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 1995;73:191-201.
114. Trifilieff A, El-Hashim A, Bertrand C: Time course of inflammatory and remodeling events in a murine model of asthma: Effect of steroid treatment. Am J Physiol Lung Cell Mol Physiol 2000;279:L1120-L1128.
115. Bonnans C, Vachier I, Chavis C, Godard P, Bousquet J, Chanez P: Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am J Respir Crit Care Med 2002;165:1531-1535.
116. 4 antagonize TNF-alpha-stimulated neutrophil-enterocyte interactions in vitro and attenuate TNF-alpha-induced chemokine release and colonocyte apoptosis in human intestinal mucosa ex vivo. J Immunol 2001;167:2772-2780.
117. 4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol 2002;168:5260-5267.
118. Munger KA, Montero A, Fukunaga M, Uda S, Yura T, Imai E, Kaneda Y, Valdivielso JM, Badr KF: Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc Natl Acad Sci USA 1999;96:13375-13380.
119. 4, is protective in experimental ischemic acute renal failure. J Am Soc Nephrol 2002;13:1657-1662.
120. 4 and related compounds: Development of new extraction techniques for lipoxins. Lab Invest 2002;82:1253-1254.
121. 4 receptor that is regulated by IL-13 and IFN-γ and inhibits TNF-α-induced IL-8 release. J Exp Med 1998;187:1285-1294.
122. Dahlén B: Leukotrienes as Mediators of Asthma Induced by Aspirin and Allergen. Stockholm, Department of Thoracic Medicine, Karolinska Institutet, 1993, p 68.
123. 4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J Immunol 2000;164:2660-2666.
124. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR: Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 2000;164:1663-1667.
125. Shinmura K, Tang X-L, Wang Y, Xuan Y-T, Liu S-Q, Takano H, Bhatnagar A, Bolli R: Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 2000;97:10197-10202.
126. Marcus AJ, Broekman MJ, Pinsky DJ: COX inhibitors and thromboregulation. N Engl J Med 2002;347:1025-1026.
127. Chandrasekharan NV, Dai H, Roos KLT, Evanson NK, Tomsik J, Elton TS, Simmons DL: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99:13926-13931 (www.pnas.org/cgi/doi/10.1073/pnas.162468699).
128. Warner TD, Mitchell JA: Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum? Proc Natl Acad Sci USA 2002;99:13371-13373 www.pnas.org/cgi/doi/10.1073/pnas.222543099.
129. Aliberti J, Hieny S, Reis e Sousa C, Serhan CN, Sher A: Lipoxin-mediated inhibition of IL-12 production by DCs: A mechanism for regulation of microbial immunity. Nat Immunol 2002;3:76-82.
130. 4 receptor. J Exp Med 1994;180:253-260.
131. 4 receptor intracellular domains result in sustained signaling. Biochemistry 2000;39:13551-13557.
132. 4. Nat Med 2002;8:1018-1023.
133. 4. J Immunol 2001;166:3650-3654.
134. Serhan CN, Jain A, Marleau S, Clish C, Colgan SP, Stahl GL, Chan L, Petasis NA, Van Dyke TE: Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators, in preparation.